Slingshot Biosciences
Slingshot Bio | Reproducible Alternative to Flow Cytometry Controls
United States · $39.3M raised
- Business Model
- B2B
- Website
- slingshotbio.com
- Total Funding
- $39.3M
- Last Round
- $11.0M Series AFeb 2023
- Rounds
- 3
About
Synthetic cell-mimic controls for flow cytometry enabling reproducible, precision research results.
Summary
Slingshot Biosciences is a Biotech company based in United States. It has raised $39.3M in total across 3 rounds, most recently a $11.0M Series A round in Feb 2023. Investors include ARCH Venture Partners, Northpond Ventures and Anterra Capital.
Tech & App Stack
12 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Feb 2023
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company